CCL2 and coronary artery disorder: In the present study, we analyzed a series of patients with stable coronary artery disease (SCAD) to determine if the plasma levels of some acylcarnitines and amino acids may improve the predictive power of several pro-inflammatory and pro-fibrotic factors [monocyte chemoattractant protein-1 (MCP-1), soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), neutrophil gelatinase-associated lipocalin [NGAL], and galectin-3 (Gal-3)] which were previously demonstrated to predict the incidence of cardiovascular events in these patients [14,15,16,17].